Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.

Jared M WeissNathan PennellAllison M DealDaniel MorgenszternDaniel S BradfordJeffrey CraneHoward Jack WestCarrie LeeChad PecotJames P StevensonWilliam IrvinMark SocinskiThomas Eldridge StinchcombeLiza C VillaruzHyman B Muss

Published in: Cancer (2020)

Fit and prefrail older patients with stage IV NSCLC should be considered for treatment with nab-paclitaxel after disease progression with doublet chemotherapy.

Keyphrases

advanced non small cell lung cancer
chemotherapy induced
community dwelling
locally advanced
middle aged
physical activity
small cell lung cancer
epidermal growth factor receptor
rectal cancer
combination therapy
replacement therapy
smoking cessation